top of page

PIQHASSO

PQR309 AND ERIBULIN FOR LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE AND TRIPLE NEGATIVE BREAST CANCER

CLINICAL TRIAL DETAILS

THIS STUDY IS AN OPEN-LABEL, NON RANDOMIZED, MULTI-CENTER, PHASE 1/2B (DOSE ESCALATION FOLLOWED BY EXPANSION PART) STUDY EVALUATING CLINICAL SAFETY, EFFICACY AND PHARMACOKINETICS OF PQR309 IN COMBINATION WITH STANDARD DOSE OF ERIBULIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE (ESCALATION PART) AND TRIPLE NEGATIVE BREAST CANCER (EXPANSION PART). LEGAL STUDY SPONSOR IS PIQUR THERAPEUTICS AG.

PIQHASSO AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

N

SITES

BREAST

6

43

I/IIb

Spain, UK

Recruitment closed

PRESS RELEASE

home_fondo_you_barra.jpg

-

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

SABCS 2016 poster

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

-

TRIAL SITES

home_fondo_you_barra.jpg
Hospital Universitario Ramón y Cajal (Spain) Instituto Valenciano de Oncología (IVO) (Spain) Hospital Universitari Vall D'Hebron (Spain) Institut Català d'Oncologia L'Hospitalet (ICO) (Spain) Churchill Hospital, Oxford (UK) Barts Cancer Institute (UK)
bottom of page